Publication Details
Abstract
Photoaging is driven by repeated ultraviolet exposure, redox imbalance, matrix metalloproteinase activation and progressive disruption of the dermal collagen network. A standardized Hericium erinaceus active system was developed by separately isolating an erinacine A-enriched mycelial fraction and an extracellular-polysaccharide (EPS) fraction from the same fermentation batch, followed by controlled 1:10 dry-basis recombination. The active dispersion contained 0.05% erinacine A and 5.2% EPS and was incorporated at 4.00% into an essence emulsion containing squalane, caprylic/capric triglyceride, glycerol and hydrogenated lecithin. The formulation remained physically stable after centrifugation and three freeze-thaw-type temperature cycles. Published H. erinaceus research shows that aqueous extracts can reduce UVA-induced MMP-1 and elastase while increasing type-I procollagen in human dermal fibroblasts, and H. erinaceus polysaccharides have been linked to antioxidant enzymes, collagen and MMP/TIMP biology in preclinical skin models. Erinacine A research in non-cutaneous models further identifies Nrf2/HO-1, iNOS, MAPK and NF-kappaB as redox-inflammatory pathways of potential mechanistic relevance. Human studies of fungal beta-glucan/chitin-glucan systems and topical phosphatidylserine provide complementary clinical context for elasticity, roughness and collagen-related endpoints. The integrated evidence supports future formulation-specific evaluation of wrinkles, roughness, elasticity and firmness while preserving clear separation between current physicochemical observations and published biological data.